PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study-Reference-Cited by-同舟云学术

PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study

Published:2022-03-09 Issue:3 Volume:39 Page:443-448
ISSN:0262-0898
Container-title:Clinical & Experimental Metastasis
language:en
Short-container-title:Clin Exp Metastasis

Author:

Mazzola Rosario,Cuccia Francesco^ORCID,Pastorello Edoardo,Salgarello Matteo,Francolini Giulio,Livi Lorenzo,Triggiani Luca,Magrini Stefano Maria,Ingrosso Gianluca,Aristei Cynthia,Franzese Ciro,Scorsetti Marta,Alongi Filippo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10585-022-10157-8.pdf

Reference23 articles.

1. Testa U, Castelli G, Pelosi E (2019) Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. Medicines 6(3):82. https://doi.org/10.3390/medicines6030082

2. Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S (2021) Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18(2):79–92. https://doi.org/10.1038/s41585-020-00400-w

3. Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22(1):98–106. https://doi.org/10.1016/S1470-2045(20)30537-4

4. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1

5. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice;Nuclear Medicine Communications;2024-04-27

2. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study;Archivos Españoles de Urología;2024

3. Comparison of Digital versus Analog 68Ga-PSMA-11 PET/CT Performance in Hormone-Sensitive Prostate Cancer Patients with Early Biochemical Recurrence or Persistence after Radical Treatment;Diagnostics;2023-11-26

4. Global research status and hotspots of radiotherapy for prostate cancer: a bibliometric analysis based on Web of Science from 2010-2022;Frontiers in Oncology;2023-08-11

5. PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer;Cancers;2023-05-17